The first Phase III data for Grunenthal GMBH’s analgesic cebranopadol in cancer pain show it was non-inferior and on the main measure even superior to prolonged-release morphine sulfate, with comparable side-effects.
The family-owned German company now wants to find a “strong” development and commercialization partner for Asian markets, including Japan, to...







